• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性期慢性髓性白血病的一线治疗选择。

Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia.

机构信息

Neil P. Shah, University of California, San Francisco, San Francisco, CA.

出版信息

J Clin Oncol. 2018 Jan 20;36(3):220-224. doi: 10.1200/JCO.2017.75.4663. Epub 2017 Dec 5.

DOI:10.1200/JCO.2017.75.4663
PMID:29206554
Abstract

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 40-year-old woman with a past medical history of hypertension and occasional premature ventricular contractions was found on routine blood work in June 2011 to have mild thrombocytosis, with a platelet count of 405,000. In November 2011, repeat analysis revealed a platelet count of 433,000, and by February 2012 her platelet count was 509,000. She had no evidence of leukocytosis or anemia and no symptoms of early satiety, night sweats, pruritus, or erythromelalgia. She was referred to a hematologist for evaluation of persistent isolated thrombocytosis in March 2012. Her spleen was not palpable, and a quantitative polymerase chain reaction (PCR) test for JAK2/V617F was negative. A bone marrow biopsy and aspiration revealed a mildly hypercellular marrow (70% to 80% cellularity), with an elevated myeloid:erythroid ratio of 5:1, increased megakaryocytes including micromegakaryocytes in the absence of increased blasts. Cytogenetic analysis revealed the presence of the Philadelphia chromosome translocation in 17 out of 20 metaphases. The remaining three metaphases were normal karyotype. Quantitative PCR for BCR-ABL1 yielded a value of 29.6% on the International Scale.

摘要

一名 40 岁女性,既往高血压病史,偶发室性期前收缩,于 2011 年 6 月常规查血时发现血小板轻度升高,血小板计数为 405000。2011 年 11 月复查时血小板计数为 433000,至 2012 年 2 月血小板计数达 509000。患者无白细胞增多或贫血,无早饱、盗汗、瘙痒或红斑性肢痛等症状。2012 年 3 月因持续性孤立性血小板增多症就诊于血液科。其脾脏未触及肿大,JAK2/V617F 定量聚合酶链反应(PCR)检测阴性。骨髓活检和抽吸显示骨髓增生活跃(70%~80%为有核细胞),粒红比增高为 5:1,巨核细胞增多,包括微巨核细胞,但无增多的原始细胞。核型分析显示 20 个中期分裂相中 17 个存在费城染色体易位,其余 3 个中期分裂相为正常核型。BCR-ABL1 的定量 PCR 检测国际标准化比值(International Scale)为 29.6%。

相似文献

1
Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia.慢性期慢性髓性白血病的一线治疗选择。
J Clin Oncol. 2018 Jan 20;36(3):220-224. doi: 10.1200/JCO.2017.75.4663. Epub 2017 Dec 5.
2
Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.慢性髓性白血病的分子监测与突变:如何充分利用酪氨酸激酶抑制剂
Am Soc Clin Oncol Educ Book. 2014:167-75. doi: 10.14694/EdBook_AM.2014.34.167.
3
[BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation].[一名携带JAK2-V617F突变的继发性骨髓纤维化患者出现BCR-ABL1阳性慢性髓性白血病]
Rinsho Ketsueki. 2017;58(4):298-302. doi: 10.11406/rinketsu.58.298.
4
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Fusion Transcript: A Case Report.达沙替尼对一名表达罕见E13a3融合转录本的高龄慢性粒细胞白血病患者的疗效:病例报告
Anticancer Res. 2019 Jul;39(7):3949-3954. doi: 10.21873/anticanres.13548.
5
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼:一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
6
Is dasatinib-related pulmonary hypertension a clinical concern?达沙替尼相关的肺动脉高压是一个临床关注点吗?
Future Oncol. 2015 Sep;11(18):2491-4. doi: 10.2217/fon.15.170. Epub 2015 Aug 17.
7
[Atypical myeloproliferative neoplasm with a small population of Philadelphia chromosome-positive clones in the bone marrow].骨髓中存在少量费城染色体阳性克隆的非典型骨髓增殖性肿瘤
Rinsho Ketsueki. 2011 Feb;52(2):73-7.
8
Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.通过外周血实时聚合酶链反应对BCR-ABL进行连续监测,可预测慢性髓性白血病患者对甲磺酸伊马替尼的骨髓细胞遗传学反应。
Br J Haematol. 2002 Sep;118(3):771-7. doi: 10.1046/j.1365-2141.2002.03705.x.
9
Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.混合表型(T/B/髓系)髓外原始细胞危象作为慢性髓性白血病的初始表现。
Exp Mol Pathol. 2018 Apr;104(2):130-133. doi: 10.1016/j.yexmp.2018.02.005. Epub 2018 Mar 1.
10
[Development of Ph negative acute myeloid leukemia in a patient with minor-BCR/ABL positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment].[在酪氨酸激酶抑制剂治疗期间获得部分细胞遗传学缓解的微小 BCR/ABL 阳性慢性髓性白血病患者发生 Ph 阴性急性髓性白血病]
Rinsho Ketsueki. 2015 Jun;56(6):681-6. doi: 10.11406/rinketsu.56.681.

引用本文的文献

1
Successful treatment of a chronic myeloid leukemia patient with extreme thrombocytosis by a combination of imatinib and interferon‑α: A case report.伊马替尼与α干扰素联合治疗慢性粒细胞白血病伴极度血小板增多症患者成功:一例报告
Exp Ther Med. 2025 Jan 16;29(3):50. doi: 10.3892/etm.2025.12800. eCollection 2025 Mar.
2
Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis.BCR-ABL1转录本类型对接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者预后的影响:一项成对和贝叶斯网络荟萃分析。
Front Oncol. 2022 Feb 10;12:841546. doi: 10.3389/fonc.2022.841546. eCollection 2022.
3
Current status and future perspectives in HER2 positive advanced gastric cancer.
HER2阳性晚期胃癌的现状与未来展望
Clin Transl Oncol. 2022 Jun;24(6):981-996. doi: 10.1007/s12094-021-02760-0. Epub 2022 Jan 29.
4
Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia.白血病干细胞作为实现慢性髓性白血病无治疗缓解的潜在靶点。
Cancers (Basel). 2021 Nov 20;13(22):5822. doi: 10.3390/cancers13225822.
5
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis.以失去主要分子反应作为分子复发定义的慢性髓性白血病酪氨酸激酶抑制剂停药:一项系统评价和荟萃分析
Front Oncol. 2019 May 14;9:372. doi: 10.3389/fonc.2019.00372. eCollection 2019.
6
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.在临床实践中慢性髓性白血病治疗中断的可行性:来自 236 例全国性系列研究的结果。
Blood Cancer J. 2018 Dec 2;8(10):91. doi: 10.1038/s41408-018-0125-0.
7
First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis.新诊断慢性髓系白血病的一线治疗策略:一项网状Meta分析
Cancer Manag Res. 2018 Sep 25;10:3891-3910. doi: 10.2147/CMAR.S177566. eCollection 2018.
8
The future of cancer treatment using precision oncogenomics.使用精准肿瘤基因组学的癌症治疗未来。
Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). doi: 10.1101/mcs.a002824. Print 2018 Apr.